Advertisement

Obesity Surgery

, Volume 19, Issue 11, pp 1574–1580 | Cite as

Apelin Levels Are Increased in Morbidly Obese Subjects with Type 2 Diabetes Mellitus

  • Federico Soriguer
  • Lourdes Garrido-Sanchez
  • Sara Garcia-Serrano
  • Jose M. Garcia-Almeida
  • Juan Garcia-Arnes
  • Francisco J. Tinahones
  • Eduardo Garcia-FuentesEmail author
Clinical Research

Abstract

Background

The physiological role of apelin in obesity and diabetes remains unclear. Although apelin has been studied in persons with different conditions, no studies have yet examined the joint influence of obesity and diabetes on apelin levels. We measured the changes in apelin levels in morbidly obese subjects, with and without diabetes, and in the inverse situation of improvement in carbohydrate metabolism as a result of bariatric surgery.

Methods

The study was undertaken in 54 morbidly obese persons, 16 of whom had type 2 diabetes mellitus, before and 7 months after undergoing bariatric surgery, and in 12 healthy, nonobese persons. Measurements were made of apelin levels and insulin sensitivity by an intravenous glucose tolerance test.

Results

The apelin levels in the morbidly obese patients prior to surgery were significantly higher than those of the controls only when the morbidly obese subjects were diabetic (P < 0.005). Apelin levels correlated significantly in the morbidly obese patients with serum triglycerides (r = 0.292, P = 0.032) and glucose (r = 0.337, P = 0.039). Bariatric surgery resulted in a significant decrease in apelin levels only in the morbidly obese subjects with impaired fasting glucose or diabetes. The change in apelin levels correlated significantly in the morbidly obese patients with the changes in serum glucose (r = 0.338, P = 0.038) and insulin sensitivity (r = −0.417, P = 0.043).

Conclusions

This study demonstrates that obesity is not the main determinant of the rise in apelin levels. The association between apelin levels and glucose concentrations and insulin sensitivity provides evidence that apelin may play a role in the pathogenesis of diabetes.

Keywords

Morbid obesity Insulin resistance Apelin Diabetes 

Notes

Acknowledgments

This work was supported in part by a grant from the Instituto de Salud Carlos III (CP04/00133) and Servicio Andaluz de Salud (0438/2006, 0255/2007). CIBER Fisiopatología de la Obesidad y Nutrición (CB06/03) and CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) are ISCIII projects. We also thank Ian Johnstone for help with the English language version of the text.

Conflict of interest

The authors declare that there was no conflict of interest associated with this study.

References

  1. 1.
    García-Fuentes E, García-Almeida JM, García-Arnés J, et al. Plasma visfatin concentrations in severely obese subjects are increased after intestinal bypass. Obesity (Silver Spring). 2007;15:2391–5.CrossRefGoogle Scholar
  2. 2.
    Tatemoto K, Hosoya M, Habata Y, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998;251:471–6.CrossRefGoogle Scholar
  3. 3.
    Masri B, Knibiehler B, Audigier Y. Apelin signalling: a promising pathway from cloning to pharmacology. Cell Signal. 2005;17:415–26.CrossRefGoogle Scholar
  4. 4.
    De Falco M, De Luca L, Onori N, et al. Apelin expression in normal human tissues. In Vivo. 2002;16:333–6.PubMedGoogle Scholar
  5. 5.
    Falcao-Pires I, Leite-Moreira AF. Apelin: a novel neurohumoral modulator of the cardiovascular system. Pathophysiologic importance and potential use as a therapeutic target. Rev Port Cardiol. 2005;24:1263–76.PubMedGoogle Scholar
  6. 6.
    Carpéné C, Dray C, Attané C, et al. Expanding role for the apelin/APJ system in physiopathology. J Physiol Biochem. 2007;63:359–73.CrossRefGoogle Scholar
  7. 7.
    Tatemoto K, Takayama K, Zou MX, et al. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept. 2001;99:87–92.CrossRefGoogle Scholar
  8. 8.
    Cheng X, Cheng XS, Pang CC. Venous dilator effect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats. Eur J Pharmacol. 2003;470:171–5.CrossRefGoogle Scholar
  9. 9.
    Kleinz MJ, Skepper JN, Davenport AP. Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul Pept. 2005;126:233–40.CrossRefGoogle Scholar
  10. 10.
    Lee DK, Cheng R, Nguyen T, et al. Characterization of apelin, the ligand for the APJ receptor. J Neurochem. 2000;74:34–41.CrossRefGoogle Scholar
  11. 11.
    Sunter D, Hewson AK, Dickson SL. Intracerebroventricular injection of apelin-13 reduces food intake in the rat. Neurosci Lett. 2003;353:1–4.CrossRefGoogle Scholar
  12. 12.
    Boucher J, Masri B, Daviaud D, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology. 2005;146:1764–71.CrossRefGoogle Scholar
  13. 13.
    Castan-Laurell I, Vítkova M, Daviaud D, et al. Effect of hypocaloric diet-induced weight loss in obese women on plasma apelin and adipose tissue expression of apelin and APJ. Eur J Endocrinol. 2008;158:905–10.CrossRefGoogle Scholar
  14. 14.
    Sorhede Winzell M, Magnusson C, Ahren B. The apj receptor is expressed in pancreatic islets and its ligand, apelin, inhibits insulin secretion in mice. Regul Pept. 2005;131:12–7.CrossRefGoogle Scholar
  15. 15.
    Li L, Yang G, Li Q, et al. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes. 2006;114:544–8.CrossRefGoogle Scholar
  16. 16.
    Erdem G, Dogru T, Tasci I, et al. Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2008;116:289–92.CrossRefGoogle Scholar
  17. 17.
    Fetner R, McGinty J, Russell C, et al. Incretins, diabetes, and bariatric surgery: a review. Surg Obes Relat Dis. 2005;1:589–97.CrossRefGoogle Scholar
  18. 18.
    Tasci I, Erdem G, Ozgur G, et al. LDL-cholesterol lowering increases plasma apelin in isolated hypercholesterolemia. Atherosclerosis. 2008;204:222–8.CrossRefGoogle Scholar
  19. 19.
    Garcia-Fuentes E, Garrido-Sanchez L, Garcia-Almeida JM, et al. Different effect of laparoscopic Roux-en-Y gastric bypass and open biliopancreatic diversion of Scopinaro on serum PYY and ghrelin levels. Obes Surg. 2008;18:1424–9.CrossRefGoogle Scholar
  20. 20.
    García-Fuentes E, García-Almeida JM, García-Arnés J, et al. Morbidly obese individuals with impaired fasting glucose have a specific pattern of insulin secretion and sensitivity: effect of weight loss after bariatric surgery. Obes Surg. 2006;16:1179–88.CrossRefGoogle Scholar
  21. 21.
    Bergman RN. Lilly lecture. Toward physiological understanding of glucose tolerance. Minimal-model approach. Diabetes. 1989;38:1512–27.CrossRefGoogle Scholar
  22. 22.
    Wei L, Hou X, Tatemoto K. Regulation of apelin mRNA expression by insulin and glucocorticoids in mouse 3 T3-L1 adipocytes. Regul Pept. 2005;132:27–32.CrossRefGoogle Scholar
  23. 23.
    Rayalam S, Della-Fera MA, Krieg PA, et al. A putative role for apelin in the etiology of obesity. Biochem Biophys Res Commun. 2008;368:815–9.CrossRefGoogle Scholar
  24. 24.
    Heinonen MV, Purhonen AK, Miettinen P, et al. Apelin, orexin-A and leptin plasma levels in morbid obesity and effect of gastric banding. Regul Pept. 2005;130:7–13.CrossRefGoogle Scholar
  25. 25.
    Tasci I, Dogru T, Naharci I, et al. Plasma apelin is lower in patients with elevated LDL-cholesterol. Exp Clin Endocrinol Diabetes. 2007;115:428–32.CrossRefGoogle Scholar
  26. 26.
    Chong KS, Gardner RS, Morton JJ, et al. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail. 2006;8:355–60.CrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2009

Authors and Affiliations

  • Federico Soriguer
    • 1
    • 2
  • Lourdes Garrido-Sanchez
    • 3
  • Sara Garcia-Serrano
    • 2
  • Jose M. Garcia-Almeida
    • 4
  • Juan Garcia-Arnes
    • 1
  • Francisco J. Tinahones
    • 3
    • 4
  • Eduardo Garcia-Fuentes
    • 1
    • 3
    • 4
    • 5
    • 6
    Email author
  1. 1.Servicio de Endocrinología y NutriciónHospital Regional Universitario Carlos HayaMálagaSpain
  2. 2.CIBER Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)ISCIIIMálagaSpain
  3. 3.CIBER Fisiopatología Obesidad y Nutrición (CB06/03)ISCIIIMálagaSpain
  4. 4.Servicio de Endocrinología y NutriciónHospital Clínico Virgen de la VictoriaMálagaSpain
  5. 5.Fundación IMABISMálagaSpain
  6. 6.Laboratorio de InvestigaciónHospital CivilMálagaSpain

Personalised recommendations